Full-Time

Marketing Communications Manager

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$140k - $150k/yr

+ Stock Options + Variable Incentive Plan

Pleasanton, CA, USA

In Person

On-site in Pleasanton, CA; 15% travel.

Category
Growth & Marketing (1)
Required Skills
Adobe Creative Suite
Social Media
Canva
Marketing
Data Analysis
Requirements
  • 5-7 years of experience in marketing or marketing communications in the medical device, healthcare, or life sciences industries
  • Bachelor’s degree in marketing, business administration, communications, or a related field (or equivalent experience)
  • Experience supporting HCP marketing, patient education, or healthcare communications initiatives
  • Ability to work in a fast-paced, high-growth environment
  • Proficiency with marketing, design, and productivity tools, including Microsoft Office, Adobe Creative Suite, Canva, and other platforms used to develop presentations, digital assets, and marketing materials
  • Excellent communication and interpersonal skills with the ability to collaborate effectively across teams
  • Strong attention to detail and project management skills
  • Experience working with external agencies or creative vendors
  • Knowledge of regulatory requirements and compliance standards for medical devices or healthcare marketing
  • Work location: Pleasanton, CA
  • Travel: 15%
Responsibilities
  • Support the development and execution of integrated marketing communications across healthcare professional and patient audiences.
  • Assist in the planning and rollout of digital campaigns, product communications, and educational initiatives that support brand awareness and technology adoption.
  • Coordinate the development of marketing materials including web content, social media assets, email campaigns, videos, presentations, and print collateral.
  • Partner with internal teams to ensure communications are consistent with brand standards, compliant with regulatory requirements, and aligned with commercial strategy.
  • Collaborate with and help manage external marketing agencies, creative partners, and vendors supporting campaign execution.
  • Support the development and execution of patient education and engagement programs, including joint education initiatives, digital campaigns, and practice-level outreach tools.
  • Help develop and manage patient communication journeys (email, in-office materials, digital touchpoints) aligned to key patient milestones.
  • Lead the development of patient-facing educational materials, including print and digital materials, videos, social media content, and FAQs,
  • Identify common patient questions and barriers to care and support the development of content that improves patient understanding and engagement.
  • Work with medical, clinical, legal, and quality/regulatory teams to ensure patient communications are accurate, compliant, and accessible.
  • Support the development of physician education materials, sales enablement tools, and promotional content used by the commercial organization.
  • Assist with marketing support for conferences, physician training programs, and educational initiatives.
  • Contribute to the development and maintenance of presentations, brochures, digital assets, and other materials used by the field team.
  • Help manage project timelines, deliverables, and workflows across marketing initiatives.
  • Assist in documenting best practices and creating repeatable tools and templates for marketing programs.
  • Track and report on key metrics across marketing programs, including engagement, campaign performance, and program adoption.
  • Support data analysis and reporting to evaluate program effectiveness and identify optimization opportunities.
  • Compile insights and recommendations to inform future marketing strategies and campaigns.

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Series F raised $40M led by Ally Bridge Group and Janus Henderson Investors.
  • CVAC system treated over 40,000 patients, advancing toward standard of care.
  • ASPIRE study at AUA showed superior clearance independent of stone burden in 101 patients.

What critics are saying

  • Boston Scientific's LithoClast Trilogy erodes market share via hospital contracts in 12-24 months.
  • Cook Medical's NGage basket undercuts CVAC pricing by 30% in 12-18 months.
  • FDA Class I recall triggers withdrawal due to 5% ureteral perforation risks in 3-9 months.

What makes Calyxo unique

  • CVAC System integrates ureteroscopy, laser lithotripsy, irrigation, and aspiration in one device.
  • SURE procedure with CVAC achieves 97% volumetric stone clearance versus standard URS.
  • Redesigned CVAC received FDA clearance in March 2024 for minimally invasive treatment.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Calyxo who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.